• 1
    Rehermann B, Fowler P, Sidney J, Person J, Redeker A, Brown M, Moss B, et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995; 181:10471058.MEDLINE
  • 2
    Penna A, Chisari FV, Bertoletti A, Missale G, Fowler P, Giuberti T, Fiaccadori F, et al. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 1991; 174:15651570.MEDLINE
  • 3
    Nayersina R, Fowler P, Guilhot S, Missale G, Cerny A, Schlicht HJ, Vitiello A, et al. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 1993; 150:46594671.MEDLINE
  • 4
    Maruyama T, McLachlan A, Iino S, Koike K, Kurokawa K, Milich DR. The serology of chronic hepatitis B infection revisited. J Clin Invest 1993; 91:25862595.MEDLINE
  • 5
    Seeff LB, Beebe GW, Hoofnagle JH, Norman JE, Buskell-Bales Z, Waggoner JG, Kaplowitz N, et al. A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. N Engl J Med 1987; 316:965970.MEDLINE
  • 6
    Moriyama T, Guilhot S, Klopchin K, Moss B, Pinkert CA, Palmiter RD, Brinster RL, et al. Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science 1990; 248:361364.MEDLINE
  • 7
    Löhr HF, Weber W, Schlaak J, Goergen B, Meyer zum Büschenfelde KH, Gerken G. Proliferative response of CD4+ T cells and hepatitis B virus clearance in chronic hepatitis with or without hepatitis B e-minus hepatitis B virus mutants. Hepatology 1995; 22:6168.MEDLINE
  • 8
    Ferrari C, Penna A, Giuberti T, Tong MJ, Ribera E, Fiaccadori F, Chisari FV. Intrahepatic, nucleocapsid antigen-specific T cells in chronic active hepatitis B. J Immunol 1987; 139:20502058.MEDLINE
  • 9
    Tsai SL, Chen PJ, Lai MY, Yang PM, Sung JL, Huang JH, Hwang LH, et al. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion. J Clin Invest 1992; 89:8796.MEDLINE
  • 10
    Löhr HF, Krug S, Herr W, Weyer S, Schlaak J, Wölfel T, Gerken G, et al. Quantitative and functional analysis of core specific T helper cell and CTL activities in acute and chronic hepatitis B. Liver 1998; 18:413424.
  • 11
    Löhr HF, Gerken G, Schlicht HJ, Meyer zum Büschenfelde KH, Fleischer B. Low frequency of cytotoxic liver-infiltrating T lymphocytes specific for endogenous processed surface and core proteins in chronic hepatitis B. J Infect Dis 1993; 168:11331139.MEDLINE
  • 12
    Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Ann Rev Immunol 1995; 13:2960.
  • 13
    Sallberg M, Hughes J, Javadian A, Ronlov G, Hultgren C, Townsend K, Anderson CG, et al. Genetic immunization of chimpanzees chronically infected with the hepatitis B virus using a recombinant retroviral vector encoding the hepatitis B virus core antigen. Hum Gene Ther 1998; 9:17191729.MEDLINE
  • 14
    Geissler M, Tokushige K, Wakita T, Zurawski VR, Wands JR. Differential cellular and humoral immune responses to HCV core and HBV envelope proteins after genetic immunizations using chimeric constructs. Vaccine 1998; 16:857867.MEDLINE
  • 15
    Pol S, Couillin I, Michel ML, Driss F, Nalpas B, Carnot F, Berthelot P, et al. Immunotherapy of chronic hepatitis B by anti-HBV vaccine. Acta Gastroenterol Belg 1998; 61:228233.MEDLINE
  • 16
    Itoh Y, Takai E, Ohnuma H, Kitajima K, Tsuda F, Machida A, Mishiro S, et al. A synthetic peptide vaccine involving the product of the pre-S(2) region of hepatitis B virus DNA: protective efficacy in chimpanzees. Proc Natl Acad Sci USA 1986; 83:91749178.MEDLINE
  • 17
    Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC, Sadovsky R, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980; 303:833841.MEDLINE
  • 18
    Böcher WO, Herzog-Hauff S, Herr W, Heermann K, Gerken G, Meyer zum Büschenfelde KH, Löhr HF. Regulation of the neutralizing anti-hepatitis B surface (HBs) antibody response in vitro in HBs vaccine recipients and patients with acute or chronic hepatitis B virus (HBV) infection. Clin Exp Immunol 1996; 105:5258.MEDLINE
  • 19
    Böcher WO, Herzog-Hauff S, Schlaak J, Meyer zum Büschenfelde K-H, Löhr HF. Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma. Hepatology 1999; 29:238244.MEDLINE
  • 20
    Townsend ARM, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 1986; 44:959968.MEDLINE
  • 21
    Falk K, Rötschke O, Stevanivic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991; 351:290296.MEDLINE
  • 22
    Böhm W, Schirmbeck R, Elbe A, Melber K, Diminky D, Kraal G, van Rooijen N, et al. Exogenous hepatitis B surface antigen particles processed by dendritic cells or macrophages prime murine MHC class I-restricted cytotoxic T lymphocytes in vivo. J Immunol 1995; 155:33133321.MEDLINE
  • 23
    Schirmbeck R, Melber K, Mertens T, Reimann J. Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: Implication for the pathogenesis of HBV-induced hepatitis. J Virol 1994; 68:14181425.MEDLINE
  • 24
    Wilson CC, Olson WC, Tuting T, Rinaldo CR, Lotze MT, Strokus WJ. HIV-1 specific CTL responses primed in vitro by blood derived dendritic cells and Th1-biasing cytokines. J Immunol 1999; 162:30703078.MEDLINE
  • 25
    Bachmann MF, Lutz MB, Layton GT, Harris SJ, Fehr T, Rescigno M, Ricciardi-Castagnoli P. Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes. Eur J Immunol 1996; 26:25952600.MEDLINE
  • 26
    Samuel D, Bismuth A, Mathieu D, Arulnaden JL, Reynes, Benhamou JP, Brechot C, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991; 337:813815.MEDLINE
  • 27
    Le Borgne S, Mancini M, Le Grand R, Schleef M, Dormont D, Tiollais P, Riviere Y, et al. In vivo induction of specific cytotoxic T lymphocytes in mice and rhesus macaques immunized with DNA vector encoding an HIV epitope fused with hepatitis B surface antigen. Virology 1998; 240:304315.MEDLINE
  • 28
    Gramzinski RA, Millan CL, Obaldia N, Hoffmann SL, Davis HL. Immune response to a hepatitis B DNA vaccine in Aotus monkeys: A comparison of vaccine formulation, route and method of administration. Mol Med 1998; 4:109118.MEDLINE
  • 29
    Höhler T, Gerken G, Notghi A, Lubjuhn R, Taheri H, Protzer U, Löhr HF, et al. HLA-DRB1*1301 and *1302 protect against chronic hepatitis B. J Hepatol 1997; 26:503507.MEDLINE
  • 30
    Egea E, Iglesias A, Salazar M, Morimoto C, Kruskall MS, Awdeh Z, Schlossman SF, et al. The cellular basis for lack of antibody response to hepatitis B vaccine in humans. J Exp Med 1991; 173:531538.MEDLINE
  • 31
    Nagafuchi S, Kashiwagi S, Okada K, Anzai K, Nakamura M, Nishimura M, Sasazuki T, et al. Reversal of nonresponders and postexposure prophylaxis by intradermal hepatitis B vaccination in Japanese medical personnel. JAMA 1991; 265:26792683.MEDLINE
  • 32
    Struve J, Aronsson, Frenning B, Forsgren M, Weiland O. Seroconversion after additional vaccine doses to non-responders to three doses of intradermally or intramuscularly administered recombinant hepatitis B vaccine. Scand J Infect Dis 1994; 26:468470.MEDLINE
  • 33
    Sylvan SP, Hellstrom UB. Characterization of hepatitis B surface antigen (HBsAg) induced interleukin-2 secretion in chronic asymptomatic carriers of HBsAg. Clin Exp Immunol 1989; 78:207213.
  • 34
    Sylvan SP, Hellstrom UB. HBsAg-induced interferon-gamma secretion in T cells from asymptomatic HBsAg carriers and HB-immune donors in vitro. Immunology 1990; 70:197202.MEDLINE
  • 35
    Honorati MC, Dolzani P, Mariani E, Piacentini A, Lisignoli G, Ferrari C, Facchini A. Epitope specificity of Th0/Th2 CD4+ T-lymphocyte clones induced by vaccination with rHBsAg vaccine. Gastroenterology 1997; 112:20172027.MEDLINE
  • 36
    Mattila PS, Pelkonen J, Makela O. Proportions of IgG subclasses in antibodies formed during vaccination with hepatitis B surface antigen. Scand J Immunol 1986; 24:699704.MEDLINE
  • 37
    Howard MC, Miyajima A, Coffman R. T-cell-derived cytokines and their receptors. In: WEPaul eds. Fundamental Immunology 3rd ed. New York: Raven. 1993;763800.
  • 38
    Allen JE, Maizels RM. Th1-Th2: Reliable paradigm or dangerous dogma? Immunol Today 1997; 18:387392.MEDLINE
  • 39
    Vingerhoets J, Vanham G, Kestens L, Penne G, Leroux-Roels G, Gigase P. Deficient T-cell responses in non-responders to hepatitis B vaccination: absence of TH1 cytokine production. Immunology Lett 1994; 39:163168.